58 news articles
A vibrant synthetic biology ecosystem has developed in the UK – promising new jobs and valuable technology
A survey of synthetic biology company start-ups in the UK is published today by SynbiCITE, the UK’s national centre for the commercialisation of synthetic biology. The study reveals a vibrant ecosystem sustaining a thriving and rapidly growing sector of the bioeconomy.
UK Synthetic Biology Start up Survey 2017
We would like to invite you to the Breakfast Seminar Launch of SynbiCITE’s UK Synthetic Biology Start-up Survey on Friday 21st July 2017, at 9.00-10:4...
CustoMem wins £100K 1st Prize in Bio-start competition
SynbiCITE and Rainbow Seed Fund congratulate CustoMem as winners of the 1st Prize in the Bio-start competition for companies using engineering biology to solve significant global problems.
Touchlight welcomes Dr. Geoff Smith
Touchlight is very pleased to welcome Dr. Geoff Smith as the Head of Innovations. Geoff brings extensive experience in genomics technologies and applications, with roles including Vice President leading Technology Development at Illumina and CEO of Cambridge Epigenetix.
Synpromics raises £5.2m of new investment
Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce that it has completed a financing round of £5.2M. Participants included existing investors Calculus Capital, the Scottish Investment Bank, the investment arm of Scottish Enterprise and private shareholders.
Two new start-up plans win BrisSynBio’s first synthetic biology entrepreneurship competition
Two start-ups' proposals have been chosen as the winners of the first competition to discover and accelerate new synthetic biology companies at the University of Bristol.
Scientists engineer baker's yeast to produce penicillin molecules
The synthetic biologists from Imperial College London have re-engineered yeast cells to manufacture the nonribosomal peptide antibiotic penicillin. In laboratory experiments, they were able to demonstrate that this yeast had antibacterial properties against streptococcus bacteria.
Lab automation or robotic scientists: Dr McClymont and Professor Freemont share their views in Nature Biotechnology
Dr David McClymont, head of automation at the London DNA Foundry, and Professor Paul Freemont, Co-director of the London DNA Foundry and the EPSRC Cen...
East African Collaborations in Practical Synthetic Biology Workshop
From the 15th-17th March 2017 SynbiCITE will attend a workshop to establish UK-East African collaborations in practical synthetic biology, taking plac...
SynbiCITE is a proud sponsor of the ‘Best Emerging UK Synthetic Biology Company’ at the OBN Awards 2017
SynbiCITE is pleased to announce once again they will be sponsoring the ‘Best Emerging UK Synthetic Biology Company’ at the 9th Annual OBN Awards, 2017. This award recognises the emerging industrial or synthetic biology company that has the most promise.
Bio-start Selects First Cohort: 15 companies join Bio-start’s inaugural synthetic biology accelerator
Bio-start is pleased to announce the 15 companies that will be joining the UK’s first synthetic biology accelerator programme. Applicants from across ...
The London DNA Foundry Launches New Website
Based at Imperial College, the London DNA Foundry is a core facility at SynbiCITE, and has recently launched a new website.
Synpromics announces a research collaboration with GE Healthcare to Extend the Toolbox for Production of Biologics
Edinburgh, UK, 4th January 2017 / Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce a research collabora...
Prokarium and Probiomed in UK-Mexico Collaboration to Scale-Up Manufacture of Thermostable Vaccines with a Focus on Diarrhoea
Keele, UK and Mexico City, MX, 4th January 2017 / Prokarium and Probiomed today announced the start of their collaboration to scale-up the manufacture...
Bio-start Competition Announces Additional Cash Prizes and Sponsors
SynbiCITE and Rainbow Seed Fund today announce new sponsors and prizes for the Bio-start competition, designed to commercialise the engineering of biology. The addition of new sponsors increases the number of prizes available to competitors including the free use of laboratory space around the UK.
LGC and Desktop Genetics receive SynbiCITE funding to develop novel methods for CRISPR genome editing analysis
Desktop Genetics and LGC have been awarded funding from SynbiCITE, the UK’s national centre for the commercialisation of synthetic biology, to develop screening and validation tools for functional genomics, cell line engineering and synthetic biology.
SynbiCITE response to Government announcement on extra investment for science
SynbiCITE welcomes yesterday’s announcement by the Government of an additional £2billion investment per year for UK science R&D by the end of this parliament. SynbiCITE Co-Director’s Professors Richard Kitney and Paul Fremont share their thoughts.
Synbio Start-up Accelerator and Mentoring Programme
Running from February – April 2017, the Bio-start accelerator will provide direct access to connections that matter most in the industry. All entrants accepted into the programme will receive substantial mentoring and exposure to our global business and investor network.
Professors Jay Keasling and Chris Voigt Announced as Keynote Speakers at the SynbiCITE & IET Engineering Biology Conference
The 1st International Conference on Engineering Biology, co-founded by SynbiCITE and the Institution of Engineering and Technology (IET), has announced world experts Professor Jay Keasling and Professor Chris Voigt as keynote speakers.
First look at the latest applications for Bio-start
Applications from a range of sectors across the UK continue to arrive for Bio-start, the competition to incentivise innovative early-stage companies a...
Touchlight Genetics announced as Best Emerging UK Synthetic Biotech Company at OBN Awards 2016
SynbiCITE congratulates Touchlight Genetics as the winner of Best Emerging UK Synthetic Biotech Company at the OBN’s 8th Annual Awards Ceremony held l...
Bio-start Confirms Sir Richard Sykes as Chair of Judging Panel
SynbiCITE and Rainbow Seed Fund today announce that Sir Richard Sykes, Chairman of the Royal Institution of Great Britain, Chairman of Imperial Colleg...
Future Innovations in Synthetic Biology Forum
The Institute of Child Health in London will host a Synthetic Biology Innovation Forum on 11th October 2016. This event will bring together leading Sy...
Bio-start Announces David Lawrence as Competition Finalist Judge
SynbiCITE and Rainbow Seed Fund today announce that Dr David Lawrence, Non-executive Director at Syngenta and Chairman of the Science and Technology A...
SynbiCITE Join BIA Promoting UK Companies at SynBioBeta, San Francisco 2016
SynbiCITE, along with the BIA – the UK’s biotechnology trade association - is headed to San Francisco, USA, to promote the UK synthetic biology industry to their American counterparts, as well as industry leaders and investors.
‘Building a Biotech Business from Scratch’: IBioIC announces a 4-day MBA ‘More Business Acumen’ from 20-24 November in Glasgow
The Industrial Biotechnology Innovation Centre (IBioIC), in association with SynbiCITE, will hold a 4-Day MBA in Glasgow from 20-24 November, aiming to develop the entrepreneurship of future biotechnology leaders.
Prokarium to Develop First Vaccine to Protect Against Sexually Transmitted and Insect-Borne Zika Infections
Keele, UK, 13th September 2016 / Prokarium today announced the start of its programme to develop an oral vaccine against Zika virus infection. Using t...
SynbiCITE to Sponsor ‘Best Emerging UK Synthetic Biotech Company’ Award at OBN Awards 2016
SynbiCITE is proud to be sponsoring the ‘Best Emerging UK Synthetic Biotech Company’ Award at the 2016 OBN awards on the 6rd of October.
SynbiCITE and Business Reporter release 'Nature Knows Best' Synthetic Biology Documentary
SynbiCITE has produced the synthetic biology documentary ‘Nature Knows Best’ in partnership with Business Reporter magazine.
SynbiCITE and Rainbow Seed Fund Announce New £200k Competition for Engineering Biology
SynbiCITE and Rainbow Seed Fund announce the launch of Bio-Start, an annual competition to support early stage companies in the field of synthetic biology.
OBN announce the finalists for Best Emerging UK Synthetic Biology Company
Oxitec winner of the 2015 Best Emerging UK SynBio Company OBN announced the finalists of its 8th Annual Awards covering Biotech, Medtech, Synthetic B...
Prokarium receives £2M in Government contracts to develop new vaccines against emerging diseases and bioterrorist threats
Keele, UK, 25th July 2016 – Prokarium today announced the award of funding from the UK and Mexican Governments for the development of three new vaccin...
Cambridge Consultants spin-out Evonetix poised to transform synthetic biology industry
Cambridge Consultants announced the launch of a new DNA synthesis spin-out company, Evonetix. The joint venture, supported by technology entrepreneur ...
The UK’s First Bio-Hackathon to take place in Cambridge
The UK’s first Bio-Hackathon takes place in Cambridge this week from 21st – 25th June.
Applications Open for Lean Launchpad for Synthetic Biology 2016
SynbiCITE is now accepting applications for the next Lean Launchpad for Synthetic Biology, which will be run from September to November 2016.
Special offer to all SynbiCITE Partners Are you an early stage venture ready to accelerate your business? Want to be part of a global network of mento...
SynbiCITE Partner CustoMem wins 2016 Althea-Imperial Prize
Customem wins £10,000 for innovative use of synthetic biology to create membranes that filter pollutants from wastewater.
UK's First Commercial Synthetic Biology Foundry Goes Into Production
SynbiCITE has officially launched its synthetic biology Foundry, providing automated end-to-end design, construction and validation of synthetic biologic components.
SynbiCITE Collaborator Bento Bioworks Completes Beta Testing
SynbiCITE collaborator and Lean Launchpad graduate Bento Bioworks has completed beta testing of Bento lab, their portable and affordable DNA lab, and have raised funding for their first production run.
Professor Paul Freemont on Radio 4
Professor Paul Freemont on BBC Radio 4 Today programme discussing latest development in synthetic biology following publication of Craig Venter's 'minimal genome' paper in Science
'Living Factories of the Future' Featured in Nature
A recent feature in Nature focuses on the various ways industry and academia hope to automate and industrialise Synthetic Biology, including SynbiCITE's upcoming DNA Foundry.
Professor Paul Freemont delivers Ellison-Cliffe Lecture
You can now watch Synbicite co-director Professor Paul Freemont deliver the Royal Society of Medicine’s annual Ellison-Cliffe Lecture.
Watch George Freeman MP, Minister for Life Sciences, launch the new strategic plan for synthetic biology 'Biodesign for the Bioeconomy' at SynbiCITE
See and hear exactly what George Freeman MP, Minister for Life Sciences, said at the launch of the Synthetic Biology Strategic Plan 2016 - 'Biodesign for the Bioeconomy'
UK Strategic Plan for Synthetic Biology 2016 Released: Biodesign for the Bioeconomy
Minister for Life Sciences George Freeman MP visits SynbiCITE to announce the release of the UK Synthetic Biology Strategic Plan 2016 — Biodesign for the Bioeconomy.
Gen9 and SynbiCITE Announce Partnership to Accelerate Technology Commercialization through Synthetic Biology
Gen9 synthetic DNA to fuel innovations by SynbiCITE community
LabGenius wins SynbiCITE BlueSkyBio prize
LabGenius was chosen because of its development of a novel DNA library synthesis technology that allows it to construct DNA libraries that are more di...
SynbiCITE leads UKTI trade mission to SynBioBeta San Francisco 2015
SynbiCITE, along with 12 of the UK's leading synthetic biology companies, is headed to San Francisco, USA, to promote the UK synthetic biology industr...
Queen’s University Belfast and Ulster University team up with SynbiCITE to deliver a ‘launch pad’ for technology start-ups
The Lean LaunchPad is an import from Silicon Valley where it is used to ‘stress test’ the commercial feasibility of new innovations. Conceived by reti...
SynBioBeta Activate! Edinburgh 2015
Following news that synthetic biology companies have raised $500million in funding so far in 2015 (compared to $75million in 2009)1, it's clear that s...
SynbiCITE sponsors new award for synthetic biology
The winner is Oxitec and the award was announced last night, Thursday 1st October at the Ashmolean Museum in Oxford. Oxitec won the award for developi...
Start-ups take off at Lean LaunchPad 2
SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology based at Imperial College London, is running a new Lean Launchpad for buddin...
Dow AgroSciences and Synthace Collaborate Using Antha
The collaboration includes a multi-seat enterprise license giving Dow AgroSciences access to Synthace’s Antha software tools. As part of the agreement...
The 1st annual engineering biology awards recognise excellence in the synthetic biology industry at SynBioBeta SF 2015
The awards are being held at the upcoming SynBioBeta SF 2015 Conference that will be hosted at the Mission Bay Conference Center, in San Francisco, Ca...
SynbiCITE academics meet Imperial alumni in Beijing
Imperial's SynbiCITE academics (L-R: Guy-Bart Stan, Karen Polizzi, John Heap, Tom Ellis) address the alumni reunionSpeaking to alumni and friends, Pre...
Visbion awarded government grant from Innovate UK SMART initiative for Synthetic Biology project
Visbion are delighted to have been chosen as the recipient of a government grant via the Innovate UK SMART initiative for a new project entering into the field of synthetic biology.
New vaccine for Chlamydia to use synthetic biology
SynbiCITE funds Prokarium to complete pre-clinical development.
SynbiCITE and Imperial College London provides a launch pad for synthetic biology start-ups
The faculty team – left to right: Karl Handelsman (Codon Capital), Stephen Chambers (SynbiCITE), Itxaso del Palacio (Lepe Partners), Paul Freemont (Im...
Synthetic biology lab backed by £2 million award
Scientists at the University of Liverpool have been awarded £2M to build a state-of-the-art DNA synthesis facility, a capability offering much needed tools for genome engineering to the academic and private sectors.